<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151628</url>
  </required_header>
  <id_info>
    <org_study_id>CP 62611</org_study_id>
    <nct_id>NCT04151628</nct_id>
  </id_info>
  <brief_title>Disrupt CAD IV With the Shockwave Coronary IVL System</brief_title>
  <official_title>Prospective, Multicenter, Single-Arm Study of the SWM-1234 in Calcified Coronary Arteries (Disrupt CAD IV Study - Japan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shockwave Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shockwave Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study design is a prospective, multicenter, single-arm study to evaluate the safety and
      effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de
      novo, calcified, stenotic coronary arteries prior to stenting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subject Population: Subjects ≥ 18 years of age with de novo, calcified coronary artery
      lesions presenting with stable, unstable or silent ischemia that are suitable for
      percutaneous coronary intervention. Approximately 72 subjects at 8 sites in Japan will be
      enrolled. Subjects will be followed through discharge, 30 days, 6, 12 and 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The Coronary IVL System is a proprietary balloon catheter system designed to enhance stent outcomes by enabling delivering of the calcium disrupting capability of lithotripsy prior to balloon dilatation at low pressures. The Coronary IVL System consists of an IVL Balloon Catheter with 2 integrated emitters, a Lithotripsy Generator, and a Connector Cable.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment and device related adverse events. Adverse events must meet definition of Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>Within 30 days of index procedure</time_frame>
    <description>Definition of MACE:
Cardiac death; or
Myocardial Infarction (MI) defined as CK-MB level &gt; 3 times the upper limit of lab normal (ULN) value with or without new pathologic Q wave at discharge (periprocedural MI) and using the Fourth Universal Definition of Myocardial Infarction beyond discharge (spontaneous MI); or
Target Vessel Revascularization (TVR) defined as revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants that had a successful index procedure and without in-hospital MACE</measure>
    <time_frame>at the end of the procedure</time_frame>
    <description>Procedural Success defined as delivering lithotripsy to the target vessel and placing a coronary stent with a residual stenosis &lt;50% (angiographic core laboratory assessed) and without in-hospital MACE.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Coronary Lithotripsy System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lithotripsy</intervention_name>
    <description>Deliver Lithotripsy to the target vessel prior to placing a coronary stent</description>
    <arm_group_label>Coronary Lithotripsy System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is ≥18 years of age

          2. Subjects with native coronary artery disease (including stable or unstable angina and
             silent ischemia) suitable for PCI

          3. For patients with unstable ischemic heart disease, biomarkers (troponin or CK-MB) must
             be less than or equal to the upper limit of lab normal within 12 hours prior to the
             procedure (note: if both labs are drawn both must be normal)

          4. For patients with stable ischemic heart disease, biomarkers may be drawn prior to the
             procedure or at the time of the procedure from the side port of the sheath.

               1. If drawn prior to the procedure, biomarkers (troponin or CK- MB) must be less
                  than or equal to the upper limit of lab normal within 12 hours prior to the index
                  procedure (note: if both labs are drawn, both must be normal)

               2. If biomarkers are drawn at the time of the procedure from the side port of the
                  sheath prior to any intervention, biomarker results do not need to be analyzed
                  prior to enrollment.

          5. Left ventricular ejection fraction &gt; 25% within 6 months (note: in the case of
             multiple assessments of LVEF, the measurement closest to enrollment will be used for
             this criteria; may be assessed at time of index procedure)

          6. Subject or legally authorized representative, signs a written Informed Consent form to
             participate in the study, prior to any study-mandated procedures

          7. Lesions in non-target vessels requiring PCI may be treated either:

               1. &gt;30 days prior to the study procedure if the procedure was unsuccessful or
                  complicated; or

               2. &gt;24 hours prior to the study procedure if the procedure was successful and
                  uncomplicated (defined as a final lesion angiographic diameter stenosis &lt;30% and
                  TIMI 3 flow (visually assessed) for all non-target lesions and vessels without
                  perforation, cardiac arrest or need for defibrillation or cardioversion or
                  hypotension/heart failure requiring mechanical or intravenous hemodynamic support
                  or intubation, and with no post-procedure biomarker elevation

                  &gt;normal; or

               3. &gt;30 days after the study procedure

             Angiographic Inclusion Criteria

          8. The target lesion must be a de novo coronary lesion that has not been previously
             treated with any interventional procedure

          9. Single de novo target lesion stenosis of protected LMCA, or LAD, RCA or LCX (or of
             their branches) with:

               1. Stenosis of ≥70% and &lt;100% or

               2. Stenosis ≥50% and &lt;70% (visually assessed) with evidence of ischemia via positive
                  stress test, or fractional flow reserve value ≤0.80, or iFR &lt;0.90 or IVUS or OCT
                  minimum lumen area ≤4.0 mm²

         10. The target vessel reference diameter must be ≥2.5 mm and ≤4.0 mm

         11. The lesion length must not exceed 40 mm

         12. The target vessel must have TIMI flow 3 at baseline (visually assessed, may be
             assessed after pre-dilatation)

         13. Evidence of calcification at the lesion site by, a) angiography, with fluoroscopic
             radio-opacities noted without cardiac motion prior to contrast injection involving
             both sides of the arterial wall in at least one location and total length of calcium
             of at least 15 mm and extending partially into the target lesion, OR by b) IVUS or
             OCT, with presence of ≥270 degrees of calcium on at least 1 cross section

         14. Ability to pass a 0.014&quot; guide wire across the lesion

        Exclusion Criteria:

          1. Any comorbidity or condition which may reduce compliance with this protocol, including
             follow-up visits

          2. Subject is a member of a vulnerable population including individuals with mental
             disability, persons in nursing homes, children, impoverished persons, persons in
             emergency situations, homeless persons, nomads, refugees, and those incapable of
             giving informed consent.

          3. Subject is participating in another research study involving an investigational agent
             (pharmaceutical, biologic, or medical device) that has not reached the primary
             endpoint

          4. Subject is pregnant or nursing (a negative pregnancy test is required for women of
             child-bearing potential within 7 days prior to enrollment)

          5. Unable to tolerate dual antiplatelet therapy (i.e., aspirin, and either clopidogrel,
             prasugrel, or ticagrelor) for at least 6 months

          6. Subject has an allergy to imaging contrast media which cannot be adequately
             pre-medicated

          7. Subject experienced an acute MI (STEMI or non-STEMI) within 30 days prior to index
             procedure, defined as a clinical syndrome consistent with an acute coronary syndrome
             with troponin or CK- MB greater than 1 times the local laboratory's upper limit of
             normal

          8. New York Heart Association (NYHA) class III or IV heart failure

          9. Renal failure with serum creatinine &gt;2.5 mg/dL, or chronic dialysis

         10. History of a stroke or transient ischemic attack (TIA) within 6 months, or any prior
             intracranial hemorrhage or permanent neurologic deficit

         11. Active peptic ulcer or upper gastrointestinal (GI) b≥leeding within 6 months

         12. Untreated pre-procedural hemoglobin &lt;10 g/dL or intention to refuse blood transfusions
             if one should become necessary

         13. Coagulopathy, including but not limited to platelet count &lt;100,000 or International
             Normalized ratio (INR) &gt;1.7 (INR is only required in subjects who have taken warfarin
             within 2 weeks of enrollment)

         14. Subject has a hypercoagulable disorder such as polycythemia vera, platelet count
             &gt;750,000 or other disorders

         15. Uncontrolled diabetes defined as a HbA1c ≥10%

         16. Subject has an active systemic infection on the day of the index procedure with either
             fever, leukocytosis or requiring intravenous antibiotics

         17. Subjects in cardiogenic shock or with clinical evidence of left-sided heart failure
             (S3 gallop, pulmonary rales, oliguria, or hypoxemia)

         18. Uncontrolled severe hypertension (systolic BP &gt;180 mm Hg or diastolic BP &gt;110 mm Hg)

         19. Subjects with a life expectancy of less than 1 year

         20. Non-coronary interventional (e.g., TAVR, MitraClip, or PFO occlusion, etc.) or
             surgical structural heart procedures within 30 days prior to the index procedure

         21. Planned non-coronary interventional (e.g., TAVR, MitraClip, or PFO occlusion, etc.) or
             surgical structural heart procedures within 30 days after the index procedure

         22. Subject refusing or not a candidate for emergency coronary artery bypass grafting
             (CABG) surgery

         23. Planned use of atherectomy, scoring or cutting balloon, or any investigational device
             other than lithotripsy

         24. Unprotected left main diameter stenosis &gt;30%

         25. Target vessel is excessively tortuous defined as the presence of two or more bends
             &gt;90º or three or more bends &gt;75º

         26. Definite or possible thrombus (by angiography or intravascular imaging) in the target
             vessel

         27. Evidence of aneurysm in target vessel within 10 mm of the target lesion

         28. Target lesion is an ostial location (LAD, LCX, or RCA, within 5 mm of ostium) or an
             unprotected left main lesion

         29. Target lesion is a bifurcation with ostial diameter stenosis ≥30%

         30. Second lesion with &gt;50% stenosis in the same target vessel as the target lesion
             including its side branches

         31. Target lesion is located in a native vessel that can only be reached by going through
             a saphenous vein or arterial bypass graft

         32. Previous stent within the target vessel implanted within the last year

         33. Previous stent within 10 mm of the target lesion regardless of the timing of its
             implantation

         34. Angiographic evidence of a dissection in the target vessel at baseline or after
             guidewire passage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg W Stone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigeru Saito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shonan Kamakura General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tenjinkai Shin-Koga Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka-Ken</state>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Higashi Tokushukai Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>065-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurakai Takahashi Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo-Ken</state>
        <zip>654-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higashi-Takarazuka Satoh Hospital</name>
      <address>
        <city>Takarazuka</city>
        <state>Hyogo-Ken</state>
        <zip>665-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johas Kanto Rosai Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa-Ken</state>
        <zip>211-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan-Kamakura General Hospital</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto-Katsura Hospital</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto-Fu</state>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki Medical Association Hospital</name>
      <address>
        <city>Miyazaki</city>
        <state>Miyazaki-Ken</state>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravascular Lithotripsy</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

